Full-Time
Confirmed live in the last 24 hours
Genetic testing and diagnostics solutions provider
$180k - $200kAnnually
Senior
Company Historically Provides H1B Sponsorship
San Diego, CA, USA
Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and monitoring. Their services include the Signatera test for cancer patients, organ health assessments for transplant patients, and various tests for women's health, such as prenatal screening and hereditary cancer risk evaluation. Natera stands out by offering a comprehensive range of specialized testing services and genetic counseling, connecting patients with counselors for personalized support. The company's goal is to improve patient care through advanced genetic testing solutions that guide treatment and health decisions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Flexible medical plans
Investment options
Time off
Workplace perks
Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.
Natera launches HEROES trial for breast cancer treatment.
Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m
Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).